Population-based Investigation of Aneurysm Incidence

Intracranial Aneurysm Clinical Trial

Official title:

Population-based Investigation of Aneurysm Incidence

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06412783
• Other study ID #: 2021YFC2501103
• Status: Completed
• Phase: N/A
• Start date: October 1, 2023
• Est. completion date: April 30, 2024

Study information

• Verified date: May 2024
• Source: Beijing Tiantan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Most intracranial aneurysms are found accidentally in neurovascular imaging. And these inspection methods are limited by the problems of instrument fixation, radiation, time-consuming, contrast agent toxicity and so on. At present, blood test is an ideal alternative method for early diagnosis. Compared with imaging examination, it is economical, general screening and convenient. Blood test is simple to operate, easy to be accepted by patients, and less invasive. Early screening of aneurysms can be performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1500
• Est. completion date: April 30, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 35-75

• Individuals with normal cognitive and communication abilities

• No serious complications, such as uncontrolled hypertension, diabetes or other chronic diseases that may affect the test results.

• Basic blood test is normal or close to normal range.

Exclusion Criteria:

• Pregnancy

• Severe heart disease, renal insufficiency, liver dysfunction and other major diseases.

• In the past 6 months, there were strokes, or other types of intracranial tumors, infections and other diseases that may affect the screening results.

• There are metal implants, including dentures, pacemakers, etc.

• Using or recently used drugs that may affect blood biomarkers ( such as anticoagulant drugs, immunosuppressive agents, etc. ).

• There are serious mental illness or cognitive dysfunction, such as claustrophobia, unable to cooperate with the completion of the test.

• It is currently participating in other clinical trials or has participated in other clinical trials in the past 3 months.

Related Conditions & MeSH terms

• Aneurysm
• Intracranial Aneurysm

Intervention

Diagnostic Test:
• blood test
performing blood tests on the participants for specific markers.

Locations

Country	Name	City	State
China	Capital Medical University Affiliated Beijing Tiantan Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Specific markers are detected	oleic acid, arachidonic acid, docasa-hexaenoic acid, interleukin 1ß, interleukin 1ra, tumor necrosis factors, SOD3, PPIA, S100A8, S100A9, MPO, APOA4, THBS1.	1hours after blood collection